Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Single Cell EPigenomic, Transcriptomic, and structural Rearrangement profiling to investigate Evolution in prostate cancer

Descrizione del progetto

Evoluzione del cancro alla prostata

Il cancro alla prostata (PrCa, Prostate Cancer) è caratterizzato da un’estensiva eterogeneità molecolare e clinica. L’obiettivo del progetto SCEPTRE, finanziato dall’UE, consiste nel comprendere il ruolo dell’epigenetica nell’eterogeneità del tumore e nell’evoluzione clonale. A tal fine, gli scienziati utilizzeranno tecnologie di sequenziamento all’avanguardia per identificare le variazioni epigenetiche, transcrittomiche e genomiche nelle cellule cancerogene. I fattori epigenetici e la metilazione del DNA hanno il potere di fungere da biomarcatori della malattia e offrono informazioni preziose sull’evoluzione dei diversi cloni del cancro. Considerando che il PrCa è il cancro più frequentemente diagnosticato negli uomini in Europa, i risultati del progetto sono estremamente significativi dal punto di vista clinico e terapeutico.

Obiettivo

Prostate cancer (PrCa) is the most frequently diagnosed cancer in men in the European Union (EU), and is a molecularly and clinically heterogeneous disease. Although the genomic and transcriptomic landscapes of PrCa have been characterized deeply, the genome-wide epigenetic landscape and its contribution to tumor heterogeneity has received less attention. The lack of single-cell methylation (with parallel single-cell transcriptomic) datasets in solid tumors (and none in PrCA) has stunted inference on clonal evolution. Consequently, the understanding of the coordinated relationship between methylation and transcriptome remains tenuous at best. Structural variants have also not been able to be accurately resolved in cancer due to the reliance on short-read sequencing, and their interplay with DNA methylation is still poorly understood. I present the project, SCEPTRE which is tightly connected to and builds upon ample expertise in the laboratories of Prof. Christoph Plass, Division Chair of Cancer Epigenomics, DKFZ, and Dr. Oliver Stegle, Division Chair of Computational Genomics, DKFZ. Within this project, I will drive the generation of novel ‘single-cell’ and ‘single-molecule long-read’ PrCa datasets, and exploit existing data resources to comprehensively assess the epigenetic and joint transcriptomic and genomic dimensions of human PrCa with the aim to examine cancer evolution. To realize this aim, I will also derive a comprehensive computational toolbox for the analysis of single-cell (and single-molecule) DNA methylation and joint multi-omic profiles. This project will deliver novel innovative ways to identify epigenetic drivers; as well as link DNA methylation for lineage tracing as a biomarker for disease progression. Moreover, the project will uncover putative relationships between the DNA methylome and transcriptome as well as between structural genetic aberrations and epigenetic changes.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) H2020-MSCA-IF-2019

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG
Contributo netto dell'UE
€ 174 806,40
Indirizzo
IM NEUENHEIMER FELD 280
69120 Heidelberg
Germania
Regione
Baden-Württemberg Karlsruhe Heidelberg, Stadtkreis
Tipo di attività
Research Organisations
Collegamenti
Costo totale
€ 174 806,40